FOLH1 and neoplasm: Compared to [177Lu]Lu-PSMA-I&T, [161Tb]Tb-SibuDAB resulted in longer mean tumor effective half-live (Th = 135 h vs. 67 h, respectively) and increased mean tumor absorbed dose (D = 6.5 vs. 2.6 Gy/GBq, respectively).